Orthofix Medical (OFIX) Q4 2024 earnings summary

Executive summary

• Achieved record Q4 and full-year 2024 net sales of $215.7M, up 8% year-over-year, and full-year net sales of $799.5M, up 7.1% year-over-year, with strong execution across all major product lines and U.S. market leadership.

• Adjusted EBITDA grew 22% in Q4 to $23.9M and 46% for the year to $67.4M, with margin expansion and positive free cash flow of $15.2M in Q4.

• Implemented a new leadership team, long-term growth plan, and integration of SeaSpine, focusing on profitable growth and operational synergies.

• Increased long-term net sales CAGR target to 6.5%–7.5% for 2025–2027, reflecting confidence in sustainable growth.

• Discontinued M6-C and M6-L artificial disc product lines, which contributed $23.4M in 2024 sales, to focus on higher-growth, differentiated areas.

Financial highlights

• Q4 2024 net sales: $215.7M, up 8% year-over-year on a constant currency basis, with all major product lines outperforming the market.

• Q4 2024 non-GAAP adjusted EBITDA: $23.9M (11.1% of net sales), up from $19.6M (9.8%) in Q4 2023.

• Full-year 2024 net sales: $799.5M, up 7.1% year-over-year constant currency.

• Q4 adjusted net income was $4.3M; full-year adjusted net income was $4.1M.

• Year-end cash and equivalents increased to $85.7M from $37.8M in 2023.

Outlook and guidance

• 2025 net sales guidance: $818M–$826M, representing 6.5% constant currency growth at midpoint, excluding discontinued M6 disc sales and a $4M FX headwind.

• 2025 adjusted EBITDA guidance: $82M–$86M, with 180 basis points of margin expansion expected.

• Long-term net sales CAGR target for 2025–2027 increased to 6.5%–7.5%.

• Positive free cash flow expected for 2025, excluding restructuring charges from M6 discontinuation.

• 2027 targets include mid-teens adjusted EBITDA margin and positive free cash flow.